Company news

Nexalis Therapeutics Limited news in 2026

Nexalis Therapeutics Limited's news releases, calls and decks from 2026, newest first.

View company

Notification regarding unquoted securities - NX1

November 10, 2026

Sep26 Appendix 4C Cash Flow Report

October 29, 2026

Sep26 Appendix 4C Cash Flow Report

October 29, 2026

Sep26 Quarterly Activities Report

October 29, 2026

Sep26 Quarterly Activities Report

October 29, 2026

Proposed issue of securities - NX1

October 29, 2026

Notification of cessation of securities - NX1

October 29, 2026

Change of Director's Interest Notice - Darryl Davies

October 5, 2026

Final Director's Interest Notice - Sean Williams

October 5, 2026

Initial Director's Interest Notice - Niv Dagan

October 5, 2026

Chair Appointment/Resignation

October 1, 2026

Removal of draft wording in the directors report HY accounts

September 1, 2026

Half Yearly Report and Accounts

August 31, 2026

Jun26 Appendix 4C Cash Flow Report

July 30, 2026

Jun26 Quarterly Activities Report

July 30, 2026

Change in substantial holding

July 29, 2026

Update on Funding Facility and Clinical Program

July 5, 2026

Binding Letter of Intent to replace existing $53m facility

May 27, 2026

Suspension from Quotation

May 25, 2026

Mar26 Appendix 4C Cash Flow Report

April 30, 2026

Significant Milestone - First Patient Screened IRX-211 Ph2

April 20, 2026

First patient dosed in IRX-616a Phase 1 trial

March 18, 2026

First eligible participant screened - phase 1 IRX-616a study

March 4, 2026

Preliminary Final Report

February 27, 2026

Dec25 Quarterly Activities Report

January 29, 2026

Dec25 Appendix 4C Cash Flow Report

January 29, 2026

Decks in 2026